Navigation Links
Automated 'Artificial Pancreas' Controls Blood Glucose Levels in Diabetes Patients for First Time
Date:6/8/2009

thm that is robust and straightforward to implement. It's become the gold standard." The UCSB APS software platform is also being used by a number of other teams working on the artificial pancreas project, but no other team has advanced yet to wholly-automated clinical trials.

Closed loop trials were performed in four patients for a mean duration of 5 hours (range of 2-7 hours) and included a meal of 30 grams of carbohydrates. The mean Low Blood Glucose Index was 0.02 (range 0-0.06), the mean High Blood Glucose Index was 9 (range 4.2-15), and the median Daily Risk Range was 'low' (range 'low' to 'moderate').

The poster was presented in New Orleans by Matthew Percival of Doyle's research group. Other researchers in the study included Dr. Eyal Dassau, senior investigator, and Dr. Benyamin Grossman, both of Doyle's group; and Sansum's Dr. Lois Jovanovic, CEO and Chief Scientific Officer, and Dr. Howard Zisser, Director of Clinical Research.

The research is part of the artificial pancreas project, which is funded by the Juvenile Diabetes Research Foundation and is being conducted by an international group of diabetes research centers. The project's first goal is to integrate an insulin pump and continuous blood glucose monitor to closely replicate a healthy pancreas for patients with type 1 diabetes--patients whose pancreases no longer produce insulin, which is used by the body to control blood glucose levels. An artificial pancreas will allow for tighter and automated control of blood glucose levels, which would significantly help to avoid the long-term complications of the disease.

UC Santa Barbara is a leading research institution. The two groups at UCSB involved in this study are the Department of Chemical Engineering, in 2007 ranked ninth in the United States and second in the University of California by U.S.
'/>"/>

SOURCE UC Santa Barbara Engineering
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. APIC Supports Automated Surveillance Technologies in Prevention of Healthcare-Associated Infections
2. iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
3. Organizations Have Federal Government Tax Incentives to Purchase Remstar Automated Systems for 2009
4. Automated Calls May Help Doctors Monitor Patients
5. Childrens Hospital of Wisconsin Extends Real-Time Asset Tracking and Automated Charge Capture to their New Patient Pavilion
6. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
7. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
8. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
9. Kirby Lesters New KL30: Fully Automated, Compact System for a Fraction of the Cost of a Robotic Dispenser
10. Automated screening process may eventually reduce additional breast cancer surgeries
11. An Evolution in Automated CO2 Laser Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Space sensors shed new light on air quality 2Health News:Space sensors shed new light on air quality 3Health News:China Medical Technologies to Announce Financial Results for the Second Quarter Ended September 30, 2007 on November 20, 2007 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Northwestern Memorial Hospital Completes Move Into Its New Prentice Women's Hospital 2Health News:Northwestern Memorial Hospital Completes Move Into Its New Prentice Women's Hospital 3
Breaking Medicine Technology:Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 1LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 2LFAGW to Run Could I Have Lupus 3F Workshop on July 26 3B Mystics Game Follows 51830 3ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 1ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 2New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 1New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 2New Data Say Uninsured Account for Nearly One Fifth of Emergency Room Visits 51823 3